Project title: Improved glucose control, with lower insulin doses, for the treatment of type 1 diabetes
People with Type 1 Diabetes rely on insulin injections for survival, however insulin use has side effects including hypoglycemia, weight gain and insulin resistance. While achieving target glucose control reduces cardiovascular disease and damage to eyes, kidney, limbs and nerves, only 21 per cent of people with type 1 diabetes achieve glucose control with insulin. There is a need for a drug that can work alongside insulin to improve glucose control and reduce insulin-induced adverse effects.
We have discovered a new pathway in the body to improve glucose tolerance, and developed new drugs that improve glucose control in type 1 diabetic mice. The TTRA project will allow us to produce the next round of drugs that will have the right pharmacokinetic properties and determine how the drug will be taken with insulin to achieve the best results. At the end of the project we will have a drug that is ready for clinical development.
TTRA Project Round: Two
- TTRA: $750,000
- Industry Contribution: $678,837 in-kind
Duration: August 2022 - July 2024